A Case of Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitors (TKI) Exhibiting Trisomy 8 and a Double Philadelphia (Ph) Chromosome, with No Signs of Disease Progression
Keywords:
chronic myeloid leukemia, double Philadelphia chromosome, trisomy 8Abstract
Ever since secondary chromosomal changes were first identified in patients with chronic myeloid leukemia (CML), questions as to whether these cytogenetic evolution patterns seen correlate with type of therapy given during chronic phase (CP) have been raised. Patients who received treatment such as hydroxyurea or busulfan have shown to have increased incidence of trisomy 8 (+8), double Philadelphia (Ph) chromosome, isochromosome i(17q) or other secondary chromosomal abnormalities. Karyotypic abnormalities were also have been reported in some of the patients who developed cytogenetic response to imatinib. In this case report, we described a case of CML in chronic phase developed complex chromosomal abnormality with +8 and an additional Ph chromosome after receiving treatment with hydroxyurea and imatinib.
Downloads
References
Abdou, S., Elshabrawy, D., Kamal, H., Tolba, F., Salem, H., El-Shebiney, M. 2013. Utility of Fluorescent in Situ Hybridization for Detection of Trisomy 8 in Chronic Myeloid Leukemia Patients. Nature & Science, 11(5), pp 60.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood (2016) 127(20):2391-405
Calabretta, B. and Perrotti, D. 2004. The biology of CML blast crisis. Blood, 103 (11), pp 4010-22.
Christian Niederwieser, Nicolaus Kroger. 2022. Transplantation in CML in the TKI era: who, when, and how? Hematology Am Soc Hematol Educ Program, 2022(1), pp 114-122.
Fabarius, A., Leitner, A., Hochhaus, A., et al. 2011. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118 (26), pp 6760–68.
Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A., Silver, R.T. 2003. The emergence of Ph−, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental Haematology, 31 (8), pp 702–707.
Kim, M., Lee, S., Jung, C.K., Lim, J., Cho, S.G., Kim, D.W., Kim, Y., Han, K., Min, W.S., Kim, C.C. 2008. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. Int J Lab Hematol, 30 (6), 508-12.
Meike, K., Pia, O., Axel, K., Stella, J.V., Caniela, E., Marius, M., Hauke, B., Inga, V., Malte, S., Ingolf, C., Inga, N. 2023 Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models. Front. Oncol. Sec. Hematologic Malignancies, 13.
Menssen, A., Hermeking, H. 2002. Characterization of the c-MYC- regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci , 99, pp 6274-6279.
Mitelman, F., Johansson, B., Mertens, F. 2001. Database of Chromosome Aberrations in Cancer. http://cgap.nci.nih.gov/Chromosomes/ Mitelman.
Sonal R. Bakshi. 2012. Trisomy 8 in leukemia: A GCRI experience. Indian Journal of Human Genetics, 18(1), pp 106–8.
Otero, L., Ornellas, M.H., Dobbin, J., De Souza Fernandez, T. 2008. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. Int J Lab Hematol. 30(4), pp 346–8.
Siti Mariam, I., Norhidayah, R., Zulaikha, A.B., Nazihah, M.Y., Rosline, H., Kausar, G.A., Sarina, S., Azlan, H. and Ankathil, R. 2022. Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. Front. Oncol. 12:720845.
Vinhas, R., Lourenco, A., Santos, S., Ribeiro, P., Silva, M., Botelho de Sousa, A., Baptista, P.V., Fernandes, A.R. 2018. A double Philadelphia chromosome-positive chronic myeloid leukemia patient, P210BCR-ABL1 and P195BCR-ABL1 isoforms. Haematologica, 103 (11):e550-E552.
Wang, W., Chen, Z., Hu, Z., Yin, C.C., Li, S., Bai, S., Bueso-Ramos, C.E., Medeiros, L.J., Hu, S. 2016. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer Journal, 6, e490.
Wang, W., Cortes, J.E., Lin, P., Khoury, J.D., Ai, D., Tang, Z. et al. 2015. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia, 29, pp 2263–66.
Wang, W., Cortes, J.E., Tang, G., Khoury, J.D., Wang, S., Bueso-Ramos, C.E. et al. 2016. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 127: 2742-2750.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Malaysian Journal of Human Genetics
This work is licensed under a Creative Commons Attribution 4.0 International License.
